PRAME peptide–HLA-A*02:01 complex (None standardized; in literature, sometimes shortened to “PRAME/HLA-A2” or “PRAME–p/HLA-A*02:01”)

The PRAME peptide / HLA-A*02:01 complex is a tumor-associated antigenic complex critical for T cell–mediated immunotherapy of cancer. PRAME (Preferentially Expressed Antigen in Melanoma) is an intracellular protein overexpressed in various cancers, including AML, sarcoma, and melanoma. Intracellular processing generates PRAME-derived peptides, which are loaded onto HLA-A*02:01—an MHC class I molecule—on the cell surface. T cells bearing T cell receptors (TCRs) specific for this complex can recognize and eliminate tumor cells presenting PRAME peptide/HLA-A*02:01. TCR mimic antibodies have also been developed to target this complex, and its restricted presence on cancer cells makes it an attractive immunotherapeutic target. However, risks include off-tumor toxicity and antigen expression heterogeneity.

Other names

PRAME–HLA-A2 complexPRAME peptide/MHC I complexPRAME antigenic peptide/HLA-A*02:01PRAME/HLA-A2pMHC (peptide-MHC) PRAME/HLA-A*02:01

TCR-T cells: Recognize PRAME peptide/HLA-A*02:01 complex on cancer cells, mediate cell killing via cytotoxicity. TCR mimic antibodies: Bind to surface PRAME peptide/HLA-A*02:01 complex, recruit immune effector mechanisms (e.g., ADCC), enhance T cell activation and cytotoxicity. Peptide vaccines: Induce endogenous T cell responses against PRAME-expressing tumor cells via presentation on HLA-A*02:01.